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Introduction: Guidelines recommendations for the treatment of COPD are poorly followed. 
This could be related to the complexity of classification and treatment algorithms. The purpose 
of this study was to validate a simpler dyspnea-based treatment algorithm for inhaled pharma-
cotherapy in stable COPD, comparing its concordance with the current Global Initiative for 
Obstructive Lung Disease (GOLD) guideline.
Methods: We enrolled patients who had been diagnosed with COPD in three primary care facili-
ties and two tertiary hospitals in Spain. We determined anthropometric data, forced expiratory 
volume in the 1st second (percent), exacerbations, and dyspnea based on the modified Medical 
Research Council scale. We evaluated the new algorithm based on dyspnea and exacerbations 
and calculated the concordance with the current GOLD recommendations.
Results: We enrolled 100 patients in primary care and 150 attending specialized care in a respira-
tory clinic. There were differences in the sample distribution between cohorts with 41% vs 26% 
in grade A, 16% vs 12% in grade B, 16% vs 22% in grade C, and 27% vs 40% in grade D for 
primary and respiratory care, respectively (P=0.005). The coincidence of the algorithm with the 
GOLD recommendations in primary care was 93% and 91.8% in the respiratory care cohort.
Conclusion: A simple dyspnea-based treatment algorithm for inhaled pharmacotherapy of 
COPD could be useful in the management of COPD patients and concurs very well with the 
recommended schema suggested by the GOLD initiative.
Keywords: COPD, treatment, algorithm, primary care
Introduction
COPD is associated with a high economic burden and is also one of the most important 
causes of morbidity and mortality worldwide.1,2 COPD has a high prevalence in the 
adult population,3–5 and most of the patients are usually treated in a primary care 
setting. However, several international studies have shown that the actual implementa-
tion of guidelines is very limited including the one published by the Global Initiative 
for Obstructive Lung Disease (GOLD).6 Pérez et al found that in the US just 12% of 
primary care physicians used the forced expiratory volume in the 1st second (FEV
1
) 
to guide their prescriptions, while Chávez et al showed how only 40% of patients had 
a treatment in agreement with the international recommendations.7,8 These data are 
similar to those shown in Denmark, Canada, Switzerland, or the People’s Republic 
of China.9–12 Moreover, only 18% of patients in Spain were being treated following 
the international standards.13
The reasons for the guidelines being poorly followed are not known, but the lack of 
real-time spirometry, incorporation of several symptoms scales of different dimension 
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and the complexity in treatment algorithms are common 
hindrances to follow international recommendations in clini-
cal practice. Recognizing these limitations and being faced 
with the fact that the most important complaint that drives 
patients to seek medical attention is the presence of dyspnea, 
first the Canadian COPD guidelines and more recently Agustí 
and Fabbri have proposed a simple symptom-driven treatment 
algorithm, but its validity has not been properly tested.14,15
We hypothesized that this simple symptom-driven treat-
ment algorithm could indeed be validated in the primary and 
secondary care settings. To test the hypothesis, we imple-
mented a dyspnea-based algorithm in two separate cohorts, 
and the use of the algorithm was then objectively compared 
with the current GOLD guidelines to inform its concordance 
and provide external validity.
Methods
We conducted a cross-sectional study in two cohorts – one 
consisted of three primary care facilities and the other 
consisted of two specialized consultation clinics (tertiary 
hospitals in Spain). In the primary care cohort, we collected 
the data of all patients with a coded COPD diagnosis who 
were under the care of nine primary care physicians between 
September 2014 and January 2015. The specialty care cohort 
consisted of outpatients derived by primary care for special-
ized attention between 2012 and 2015. COPD patients in each 
specialized consultation were selected consecutively.
In both study cohorts, we determined anthropometric data 
(age, sex, and BMI, calculated as weight in kilograms divided 
by the square of height in meters). The FEV
1
% predicted and 
absolute were measured using American Thoracic Society/
European Respiratory Society (ATS/ERS) standards.16 
Exacerbations were defined as any episode of worsening of 
dyspnea, cough, or sputum requiring antibiotics or systemic 
corticosteroids or admission to the hospital due to COPD 
exacerbation. The intensity of dyspnea was evaluated by the 
modified Medical Research Council scale (mMRC).17 The 
common inclusion criteria for both cohorts included being 
at least 40 years old, having a history of smoking (pack-
year .10), and being able to perform spirometry properly. 
All the patients had to be in stable condition for at least 
6 weeks, including all comorbidities with possible interfer-
ence with dyspnea evaluation, and receiving optimal medical 
therapy from either the primary or specialized physician 
criteria. COPD was defined by a post-bronchodilator (400 µg 
of albuterol) spirometry showing an FEV
1
/ forced vital capac-
ity (FVC) ,0.718 and FEV
1
 lower than 80% predicted using 
standard predictive equations in Spain.19 All participants 
signed the informed consent, and the study was approved 
by the ethics committees of both the University Hospital of 
Gran Canaria Dr Negrín and the University Hospital Nuestra 
Señora de la Candelaria.
Treatment algorithm
The algorithm was based on dyspnea and exacerbations 
as proposed by the Canadian guidelines and others14,15 
(Figure 1). Patients were divided according to the dyspnea 
score, measured by the mMRC scale, into a high- or a 
low-dyspnea score group. If the patient had a low dyspnea 
score (#1 using the mMRC dyspnea scale), one long-acting 
bronchodilator was given. Two bronchodilators were given 
from the beginning if the patient had a high dyspnea score 
($2 mMRC dyspnea scale). If there were $2 exacerbations 
in the previous year, inhaled corticosteroids were added to 
Figure 1 Proposed treatment algorithm.
Abbreviation: mMRC, Modified Medical Research Council scale.
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the treatment, independently of the dyspnea degree. Short-
acting bronchodilators were given only for symptom relief.
Validation with the 2011 gOlD 
recommendations
All patients were classified by both the GOLD criteria (using 
the mMRC score to measure dyspnea) and by the proposed 
algorithm. Treatment was estimated for both options and 
the degree of coincidence was calculated as a percentage. 
Coincidence with the GOLD recommendations was achieved 
if the therapy proposed matched one of the suggestions given 
by the GOLD document (first or second choice indistinctly). 
Non-coincidence was achieved when no agreement with the 
GOLD recommendations was found. Possible coincidence 
was achieved if one of the GOLD recommendations was 
included in the options provided by the tested algorithm.
statistical analysis
The sample size was calculated assuming a rate of coinci-
dence close to 90% for each one of the cohorts considered. 
A sample size of 96 patients per cohort would estimate 
the aforementioned rates with an error bound of 6% and a 
confidence level of 95%.
Categorical variables were expressed as frequencies and 
percentages, and continuous variables as mean and standard 
deviation (SD). The percentages were compared using the 
chi-square (χ2) test or the linear association test and the 
means by the Student’s t-test. The rates of coincidence were 
estimated by means of 95% confidence intervals (CI) using 
the bootstrap methods. Kappa index and similar equations 
cannot be used in this setting due to the multiple treatment 
choices contained in each GOLD grade. The statistical sig-
nificance was set at P,0.05. Analyses were performed with 
the R package binGroup.20
Results
All the patients in the primary care (n=100) and respiratory 
cohort (n=150) had spirometrically defined COPD confirmed 
using the GOLD or the lower limit of normal criteria. The 
characteristics of the sample are shown in Table 1. The 
severity distribution by GOLD grades was different between 
the primary care and the specialized cohorts, being more 
severe in the specialized one (P,0.005). The perception of 
dyspnea was lower in patients with higher FEV
1
 (percent 
predicted) and higher in patients with the lowest values. 
Indeed, the average FEV
1
 value was 70.8% in patients with 
the lowest score in the mMRC scale and 35% in those with 
the highest score (P,0.001).
In the primary care cohort, the distribution of patients 
by GOLD grades was as follows: A=41%, B=16%, C=16%, 
and D=27%. The correspondence of the proposed algorithm 
with the GOLD treatment recommendations in the primary 
care cohort was 93% (95% CI =88.0%–98.0%), while 7% 
had possible coincidence. This group was limited to GOLD 
grade C1 (,2 exacerbations and FEV
1
% ,50%) which 
accounted for 43.7% of grade C (Table 2). However, the pro-
portion of patients that actually followed the GOLD treatment 
recommendations was 36%. The agreement in grade A was 
23%, while in grades B, C, and D was 36%, 23%, and 62% 
respectively. The proportion of patients treated with inhaled 
corticosteroids was 47% in the primary care cohort, being 41% 
in grade A, 12% in B, 10% in C, and 62% in D. There were 
no differences with the hospital cohort in the mean number of 
exacerbations in the previous year or in the mMRC scale.
In the respiratory care cohort, the distribution of patients 
by GOLD grades was as follows: 26% in grade A and 
Table 2 rate of coincidence of the new algorithm with current 
gOlD recommendations (primary care, respiratory care, and 
both cohorts together)
Cohort Total
Primary Respiratory
Coincidence
n 93 137 228
% 93.0 91.8 92.3
Possible coincidence
n 7 13 19
% 7.0 8.2 7.7
Total
n 100 150 250
Abbreviation: gOlD, global Initiative for Obstructive lung Disease.
Table 1 Main characteristics of the primary and specialized care 
cohorts
Primary 
care cohort
N=100
Respiratory 
care cohort
N=150
P-value
age, years 65.6±10.6 61.8±9.7 0.004
Male/female, % 67.0/33.0 57.5/42.5 0.134
BMI 26.86±5.21 26.53±4.97 0.600
FeV1% 66.6±22.7 57.4±20.5 0.001
exacerbations 0.464*
none 46 (46.0) 68 (45.3)
1 22 (22.0) 27 (18.0)
2 17 (17.0) 24 (16.0)
$3 15 (15.0) 31 (20.7)
mMrC $2 43 (43.0) 78 (52.0) 0.163
gOlD grade 0.005*
a 41 (41.0) 39 (26.0)
B 16 (16.0) 18 (12.0)
C 16 (16.0) 35 (22.0)
D 27 (27.0) 60 (39.9)
Notes: Data are shown as mean ± sD and frequencies (%); *linear association test.
Abbreviations: gOlD, global Initiative for Obstructive lung Disease; mMrC, 
modified Medical Research Council scale; SD, standard deviation.
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12%, 22%, and 40% in grades B, C, and D, respectively. 
The correspondence of the proposed algorithm with the 
GOLD recommendations in this sample was 91.8% (95% 
CI =87.8%-96.6%), while 8.2% had possible coincidence. 
This group was also limited to GOLD grade C1. The propor-
tion of patients that actually followed the GOLD treatment 
recommendations was 63%. The agreement in grade A was 
31%, while in grades B, C, and D it was 52%, 71%, and 63% 
respectively. The proportion of patients treated with inhaled 
corticosteroids was 37% in the specialized cohort, being 24% 
in grade A, 35% in B, 33% in C and 56% in D.
When the algorithm proposed was assessed by means of 
FEV
1
% in the whole cohort, we found a 100% concordance 
in subjects with FEV
1
% .50%, while 18.8% of subjects with 
FEV
1
% ,50% had possible coincidence. The correspondence 
of the algorithm with the GOLD recommendations in the 
whole sample (n=250) was 92.3% (95% CI =89.1%–95.6%), 
while 7.7% had possible coincidence (Figure 2).
Discussion
This study shows that once the diagnosis of COPD has been 
spirometrically confirmed, a simplified dyspnea-based inhaled 
treatment algorithm has an excellent (92.3%) concordance in 
the primary and specialty outpatient clinics outlined within the 
2011 GOLD recommendations. We believe this simple algo-
rithm could help improve acceptance by busy clinicians.
The implementation of COPD guidelines independently 
of location is very limited, and given the wide presence and 
large burden of disease, the need to improve the quality on 
COPD treatment in any setting would be advisable. There 
have been some proposals that have attempted to simplify 
the treatment algorithm of COPD, anchoring its approach 
on the grading of dyspnea, the most important symptom 
affecting patients with COPD and the one that has important 
prognostic implications.14,15 The Canadian COPD guidelines 
have centered their therapy on increasing symptoms,15 while 
Agustí and Fabbri14 have published a simplified algorithm 
that coincides in principle with the Canadian approach. 
Validation of this approach could provide an easier way to 
direct patient treatment and could help health care providers 
to avoid confusion surrounding COPD treatment, and thus 
help achieve a better and more rational therapy. By improving 
treatment accuracy, this approach could also contribute to 
save resources, as it has been shown that providing an appro-
priate treatment to COPD patients who may be receiving 
wrong prescriptions might save ~700 euros per year.13 In 
2011, the GOLD committee suggested a new non-evidence-
based grading schema that aims to direct therapy and has 
become the desirable standard for COPD pharmacotherapy 
guidance. The most important finding in this study is the high 
concordance between this simple dyspnea-driven algorithm 
and the GOLD guidelines both in the primary and in the 
specialty care settings. An algorithm based on dyspnea is 
simple and easy to understand, primarily because it is based 
on the most frequent symptom for which patients seek medi-
cal consultation. In addition, accepted scales, like the mMRC 
scale, very much resemble the widely used New York Heart 
Association functional classification of heart failure that 
has also been shown to be an important prognostic tool for 
patients with COPD. The relevance of dyspnea as the main 
prognosis symptom is supported by the studies of Nishimura 
et al21 and Almagro et al,22 while Celli et al23 included dyspnea 
Figure 2 Whole sample distribution by gOlD grades.
Note: Colors show coincidence, possible coincidence, or non-coincidence in the whole cohort.
Abbreviations: gOlD, global Initiative for Obstructive lung Disease; laBa, long-acting beta adrenergic; laMa, long-acting anticholinergic.
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in the BODE index, proving itself as one of the best predic-
tors in the index.23
This treatment algorithm lacks pulmonary function tests 
as a mandatory way to follow the effect of initial therapy. 
Neither the GOLD document nor other COPD guidelines 
have reached a consensus yet regarding the necessary or 
appropriate time to perform a spirometry in a stable patient. 
In fact, Casanova et al24 have recently shown that the FEV
1
% 
change over time did not relate directly to mortality.24 
However, a spirometry may help determine the degree of 
objective response, and until more data are available, we 
may need to depend on the clinician judgment. On the other 
hand, by not performing sequential spirometry, we probably 
avoid a practical problem in busy clinical settings. There 
are several reasons why pulmonary function tests are not 
carried out as they should be, such as the lack of spirometer 
or qualified staff to perform the technique and also lack of 
knowledge about interpretation of the results. We believe 
that clinical decisions in daily practice are made based on 
symptoms rather than on function tests. Without spirometry, 
we have observed a 92.3% correspondence with the treat-
ment proposed by the GOLD document, so the combination 
of exacerbations and symptoms are probably as useful as 
FEV
1
% in clinical daily practice, allowing us to exclude the 
FEV
1
 from the algorithm of the initial treatment approach for 
COPD. The lack of spirometry in this proposal does not mean 
that pulmonary function tests are not worthy. Spirometry is 
an essential tool to diagnose COPD and to exclude other 
potential causes of dyspnea not due to COPD, such as asthma, 
interstitial lung disease with restrictive physiology, and even 
cardiac problems where the spirometry may be normal. It also 
characterizes COPD patients better, and its performance over 
2 years in order to determine disease progression has been 
proven, even in a clinically stable disease.25 Obviously, in 
patients with worsening symptoms, spirometry must be per-
formed, as patients with a rapid decline have a worse overall 
prognosis.26 Finally, we believe that the current algorithm can 
serve as the basis for the evaluation of added spirometry with 
outcomes as the yardstick to determine its utility.
In the dyspnea-driven algorithm, the use of short bron-
chodilators as main therapy has been avoided and has been 
recommended just for symptom relief. COPD is a chronic 
disease and the evidence provided by every study where 
long-acting versus short-acting bronchodilators have been 
compared, indicates superiority not only in lung function but 
also in patient-related outcomes.27,28 Moreover, the frequency 
of administration, the lack of strength compared with long-
acting drugs, and the probable progression of the disease led 
us to exclude these medications as main therapy for COPD. 
We think this decision helps minimize errors in treatment by 
reducing confusion in busy clinical practice.
We are aware that this algorithm has some limitations 
as well. First, we do not have a 100% concordance with the 
GOLD document. This discordance is located in patients in 
grade C1 (,2 exacerbations and a FEV
1
% ,50%). Giving 
long-acting anticholinergic (LAMA) matches one of the 
choices proposed by GOLD, but giving long-acting beta 
adrenergic (LABA) is not contemplated in GOLD recom-
mendations. We are acquainted with the fact LAMAs have 
more evidence than LABAs, but the maintenance of both 
options keeps the algorithm simple and easier to apply. Drugs 
like indacaterol, vilanterol, or olodaterol have a similar degree 
of bronchodilation as tiotropium and reduce exacerbations 
in almost the same proportion, so they could be considered 
appropriate alternative choices. In addition, grade C is the less 
populated group in the GOLD classification in several studies, 
thereby minimizing this discrepancy that overall remains very 
small.29 Another potential limitation is the use of a categori-
cal scale such as mMRC to measure dyspnea. Dyspnea is a 
continuum and as such it is not biologically precise when 
measured in five steps. Dyspnea scales also need to be used 
with caution, as comorbidities must necessarily be ruled out 
in order to measure just COPD breathlessness. However, the 
mMRC scale is simple, and it resembles the New York Heart 
Association scale of functional disability, which has great 
diffusion and acceptance among primary care doctors, and very 
importantly, it is an excellent mortality predictor in COPD.
In this study, we left out drugs like roflumilast, theo-
phyline, antibiotics, and other treatment options like oxygen, 
rehabilitation, or volume reduction because a patient who is 
not well controlled with the powerful inhaled medications 
available in regular care would be best served by a consul-
tation with a specialist in COPD who can then address the 
potential use of these therapies.
A question that could be raised is what would happen 
when a patient with low dyspnea score has no improvement 
with one long-acting bronchodilator. We think that, after 
excluding other causes of dyspnea, another long-acting 
bronchodilator should be added. This will be a logical step 
up in the treatment algorithm. Since this dyspnea-based 
algorithm is meant to be used in clinical practice, we have 
defined improvement as having a decrease of at least one 
step in the mMRC scale. This longitudinal approach should 
be validated in the future in a prospective study.
Conclusion
In summary, we have explored and validated the imple-
mentation of a simple, practical algorithm for inhaled 
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pharmacotherapy in stable COPD that centers on the symp-
tom of dyspnea and the presence of exacerbations. This 
algorithm has a 92.3% agreement with the current GOLD 
recommendations in the primary and specialty setting. This 
approach could help busy providers to implement good phar-
macological care for COPD treatment in clinical practice.
Disclosure
The authors report no conflicts of interest in this work.
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